- Home
- RAVE vs EQ Comparison
RAVE vs EQ Comparison
Compare RAVE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAVE
- EQ
- Stock Information
- Founded
- RAVE 1958
- EQ 2017
- Country
- RAVE United States
- EQ United States
- Employees
- RAVE N/A
- EQ N/A
- Industry
- RAVE Restaurants
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- RAVE Consumer Discretionary
- EQ Health Care
- Exchange
- RAVE Nasdaq
- EQ Nasdaq
- Market Cap
- RAVE 37.2M
- EQ 31.1M
- IPO Year
- RAVE N/A
- EQ 2018
- Fundamental
- Price
- RAVE $2.56
- EQ $0.88
- Analyst Decision
- RAVE
- EQ Buy
- Analyst Count
- RAVE 0
- EQ 2
- Target Price
- RAVE N/A
- EQ $5.00
- AVG Volume (30 Days)
- RAVE 46.7K
- EQ 2.2M
- Earning Date
- RAVE 02-06-2025
- EQ 03-24-2025
- Dividend Yield
- RAVE N/A
- EQ N/A
- EPS Growth
- RAVE 37.66
- EQ N/A
- EPS
- RAVE 0.18
- EQ N/A
- Revenue
- RAVE $12,236,000.00
- EQ $45,914,000.00
- Revenue This Year
- RAVE N/A
- EQ $4.77
- Revenue Next Year
- RAVE N/A
- EQ N/A
- P/E Ratio
- RAVE $14.26
- EQ N/A
- Revenue Growth
- RAVE 3.25
- EQ 7.70
- 52 Week Low
- RAVE $1.64
- EQ $0.49
- 52 Week High
- RAVE $3.36
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- RAVE 51.28
- EQ 58.42
- Support Level
- RAVE $2.47
- EQ $0.85
- Resistance Level
- RAVE $2.68
- EQ $0.98
- Average True Range (ATR)
- RAVE 0.14
- EQ 0.10
- MACD
- RAVE 0.03
- EQ 0.01
- Stochastic Oscillator
- RAVE 70.00
- EQ 62.50
About RAVE Rave Restaurant Group Inc.
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The company-owned restaurant segment includes sales and operating results for all company-owned restaurants. The Pizza Inn Franchising segment accounts for the company's revenue. Geographically, it generates the majority of the revenue from the United States.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.